View ValuationBioethics 将来の成長Future 基準チェック /06現在、 Bioethicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bioethics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BOTH - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024N/A000N/A9/30/2024N/A000N/A6/30/2024N/A000N/A3/31/2024N/A000N/A12/31/2023N/A000N/A9/30/2023N/A000N/A6/30/2023N/A000N/A3/31/2023N/A000N/A12/31/2022N/A000N/A9/30/2022N/A000N/A6/30/2022N/A000N/A3/31/2022N/A000N/A12/31/2021N/A000N/A9/30/2021N/A000N/A6/30/2021N/A000N/A3/31/2021N/A000N/A12/31/2020N/A000N/A9/30/2020N/A000N/A6/30/2020N/A000N/A3/31/2020N/A000N/A12/31/2019N/A000N/A9/30/2019N/A000N/A6/30/2019N/A000N/A3/31/2019N/A000N/A12/31/2018N/A000N/A9/30/2018N/A0N/A0N/A6/30/2018N/A0N/A0N/A3/31/2018N/A0N/A0N/A12/31/2017N/A0N/A0N/A9/30/2017N/A0N/A0N/A6/30/2017N/A0N/A0N/A3/31/2017N/A0N/A0N/A12/31/2016N/A0N/A0N/A9/30/2016N/A0N/A0N/A6/30/2016N/A0N/A0N/A3/31/2016N/A0N/A0N/A12/31/2015N/A0N/A0N/A9/30/2015N/A0N/A0N/A6/30/2015N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BOTHの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BOTHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BOTHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BOTHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BOTHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BOTHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/10 16:38終値2025/11/13 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioethics, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.